Lisa Jeffers1, Patrick J Morrison2, Eilis McCaughan3, Donna Fitzsimons4. 1. Belfast Health and Social Care Trust, Department of Genetics, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK. Electronic address: lisa.jeffers@belfasttrust.hscni.net. 2. Belfast Health and Social Care Trust, Department of Genetics, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK. 3. Institute of Nursing Research, University of Ulster, Coleraine BT52 1SA, UK. 4. Institute of Nursing Research, University of Ulster, Jordanstown BT37 0QB, UK; Belfast Health and Social Care Trust, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK.
Abstract
PURPOSE: Little is known about how women with hereditary breast and/or ovarian cancer who test positive for a BRCA gene manage the impact of a positive test result on their everyday lives and in the longer term. This study defined the experience and needs of women with hereditary breast and ovarian cancer and a positive BRCA test over time. METHODS: A grounded theory approach was taken using qualitative interviews (n = 49) and reflective diaries. Data collected from December 2006 until March 2010 was analysed using the constant comparative technique to trace the development of how women manage their concerns of inherited cancer. RESULTS: A four stage substantive theory of maximising survival was generated that defines the experience of women and how they resolve their main concerns. The process of maximising survival begins prior to genetic testing in women from high risk families as they expect to get a cancer diagnosis at some time. Women with cancer felt they had experienced the worst with a cancer diagnosis and altruistically tested for the sake of their children but a positive test result temporarily shifted their focus to decision-making around their personal health needs. CONCLUSION: This study adds to clinical practice through raising awareness and adding insights into how women cope with living with inherited cancer risk and the personal and familial ramifications that ensue from it. A clear multi-professional structured care pathway for women from genetic testing result disclosure to undergoing risk-reducing surgery and/or surveillance should be developed.
PURPOSE: Little is known about how women with hereditary breast and/or ovarian cancer who test positive for a BRCA gene manage the impact of a positive test result on their everyday lives and in the longer term. This study defined the experience and needs of women with hereditary breast and ovarian cancer and a positive BRCA test over time. METHODS: A grounded theory approach was taken using qualitative interviews (n = 49) and reflective diaries. Data collected from December 2006 until March 2010 was analysed using the constant comparative technique to trace the development of how women manage their concerns of inherited cancer. RESULTS: A four stage substantive theory of maximising survival was generated that defines the experience of women and how they resolve their main concerns. The process of maximising survival begins prior to genetic testing in women from high risk families as they expect to get a cancer diagnosis at some time. Women with cancer felt they had experienced the worst with a cancer diagnosis and altruistically tested for the sake of their children but a positive test result temporarily shifted their focus to decision-making around their personal health needs. CONCLUSION: This study adds to clinical practice through raising awareness and adding insights into how women cope with living with inherited cancer risk and the personal and familial ramifications that ensue from it. A clear multi-professional structured care pathway for women from genetic testing result disclosure to undergoing risk-reducing surgery and/or surveillance should be developed.
Authors: Katherine Karakasis; Julia V Burnier; Valerie Bowering; Amit M Oza; Stephanie Lheureux Journal: Front Oncol Date: 2016-05-11 Impact factor: 6.244
Authors: Chloe A Logue; Julia Pugh; Philip Foden; Reem D Mahmood; Robert D Morgan; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson Journal: Sex Med Date: 2021-12-15 Impact factor: 2.491